Navigation Links
Endologix to Present at Three Upcoming Conferences

IRVINE, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences. The first presentation will be at the Canaccord Adams 3rd Annual Cardiovascular Conference at the Nikko Hotel in San Francisco, CA.

         Event:  Canaccord Adams 3rd Annual Cardiovascular Conference
         Date:   Tuesday, November 10, 2009
         Time:   11:00 a.m. PT

The second presentation will be at the Lazard Capital Markets 6th Annual Healthcare Conference at the St. Regis Hotel in New York City.

         Event:  Lazard Capital Markets 6th Annual Healthcare Conference
         Date:   Wednesday, November 18, 2009
         Time:   10:00 a.m. ET

The third presentation will be at the Piper Jaffray 21st Annual Health Care Conference at the New York Palace Hotel in New York City.

         Event:  Piper Jaffray 21st Annual Health Care Conference
         Date:   Tuesday, December 1, 2009
         Time:   2:30 p.m. ET

An audio Web cast of the Company's presentations will be available by visiting the investor relations section of Endologix's Web site at A replay of the presentations will be available for 30 days.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at

    ----------------                  ------------------
    Endologix, Inc.                   The Ruth Group
    John McDermott, CEO               Nick Laudico (646) 536-7030
    (949) 595-7200                    Zack Kubow (646) 536-7020

SOURCE Endologix, Inc.

SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Endologix Announces Pricing of Public Offering of Common Stock
2. Endologix Reports 42% Second Quarter 2009 Revenue Growth
3. Endologix to Report Second Quarter 2009 Financial Results on July 22, 2009
4. Endologix Added to Russell Indexes
5. Endologix Announces Live Web Cast of Presentation in SMH Capital Small Cap Spotlight on June 17, 2009 at 4:15 p.m. ET
6. Endologix Receives Nasdaq Letter on Director Independence
7. Endologix Announces Full Commercial Launch of IntuiTrak Express Delivery System
8. Data for EntreMeds ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
9. Formatta Presents Forms-Driven Business Process Optimization Webinar for Healthcare on Thursday, November 19 at 1 p.m. Eastern
10. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
11. Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... 2016 , ... Marcy was in a crisis. Her son James, eight, was out of control. ... and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... rocks at my other children and say he was going to kill them. If ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... of Australia,s successful biotechnology scientists, Dr ... company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm is ... the ASX. Noxopharm is a clinic-ready company with its ... clinical study later this year. ... facing cancer patients - the ability of cancers to become resistant ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: